Ann DeWitt

Ann is a General Partner at The Engine. She serves as a Board Member for Biobot Analytics, Cellino, Lucy Therapeutics, Kytopen, Quaise, Copernic Catalyst, Droplet Biosciences, Kano Therapeutics, Syzygy Plasmonics, and Vaxess Technologies.

Ann was most recently at Sanofi where she held senior roles in business development and strategic venture investment. Prior to Sanofi, she was at Flagship Pioneering. Ann started her career in R&D at 3M Company, working across fields of materials, biology and engineering. Ann holds an MBA from Harvard and a PhD in Chemical Engineering from MIT. She served on the Board of Women in the Enterprise of Science and Technology and is on the Life Science Council of Springboard Enterprises.